Instrument Inactif

Cours Durata Therapeutics Inc

Actions

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

Durata Therapeutics : Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults	01/06/15
Durata Therapeutics : Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections	27/05/15
Durata Therapeutics : Actavis Confirms Generic Letairis® Patent Challenge	08/04/15
Durata Therapeutics : Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors	03/04/15
Durata Therapeutics : Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan	12/03/15

Secteur

	Varia. 1 janv.	Capi.
IQVIA HOLDINGS INC.	+1,51 %	42,75 Md
LONZA GROUP AG	+49,22 %	41,61 Md
MODERNA, INC.	+8,57 %	41,34 Md
CELLTRION, INC.	-12,36 %	26,59 Md
ICON PUBLIC LIMITED COMPANY	+8,92 %	25,49 Md
ALNYLAM PHARMACEUTICALS, INC.	-25,13 %	18,12 Md
MEDPACE HOLDINGS, INC.	+29,17 %	12,24 Md
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3,12 %	11,76 Md
UNITED THERAPEUTICS CORPORATION	+6,35 %	11 Md